Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Oral supplementation of L
Change history 13 February 2024 A Correction to this paper has been published: Abbreviations AE: Adverse event APRI: Aspartate aminotransferase to platelet ratio biw: Twice weekly bpm: Beats per min DG: Dose group ELF: Enhanced liver fibrosis EoT: End of treatment Fib-4: Fibrosis-4 GCGR: Glucagon receptor GI: Gastrointestinal GIPR: Glucose-dependent insulinotropic polypeptide receptor GLP-1R: Glucagon-like peptide-1 receptor MCPMod: Multiple comparisons procedure with modelling MMRM: Mixed model for repeated measures NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis PGI-S: Patient Global Impression of Severity qw: Once weekly SMBG: Self-monitoring of blood glucose TEAE: Treatment-emergent adverse event TFEQ-R18 V2: Three-Factor Eating Questionnaire VAS: Visual analogue scale References Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Y.CachauR.ChoiJ
Well-done and overcooked meat and poultry tend to have the highest levels
PubChem CID: 125672
